Salah Abohelaika
Salah Abohelaika publishes mostly in Cardiology and Cardiovascular Medicine, Infectious Diseases and Endocrinology, Diabetes and Metabolism, on topics such as Atrial Fibrillation Management and Outcomes, Pharmacogenetics and Drug Metabolism and Hemoglobinopathies and Related Disorders.
- World rank
- #2,641,490 of 7,710,434 ranked researchers
- Rank in Saudi Arabia
- #11,167 of 25,688
- Works
- 33
- Citations
- 311
- Citations per work
- 9.4
What does Salah Abohelaika research?
Salah Abohelaika's work is mostly in Medicine (44%), Pharmacology, Toxicology and Pharmaceutics (5%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Everything else1751.1%
- Health Sciences1443.6%
- Medicine1443.6%
- Life Sciences25.3%
- 1Cardiology and Cardiovascular Medicine20% of their works
- 2Infectious Diseases6% of their works
- 3Endocrinology, Diabetes and Metabolism6% of their works
- 4Pharmacology5% of their works
- 5Genetics5% of their works
- 6Hematology5% of their works
Research topics
- Atrial Fibrillation Management and Outcomes
- Pharmacogenetics and Drug Metabolism
- Hemoglobinopathies and Related Disorders
- Venous Thromboembolism Diagnosis and Management
- Advanced Glycation End Products research
- Antiplatelet Therapy and Cardiovascular Diseases
- Long-Term Effects of COVID-19
- Vitamin K Research Studies
Which keywords describe Salah Abohelaika's research?
The keywords of their largest research topics: Anticoagulant Therapy, Atrial Fibrillation, Cytochrome P450, Pharmacogenetics, Sickle-cell Disease, Thalassemia, Antithrombotic Therapy and Venous Thromboembolism.
- Vitamin K
- Neurologic Manifestations
- Clopidogrel
- Aspirin
- Venous Thromboembolism
- Thalassemia
- Pharmacogenetics
- Atrial Fibrillation
- Anticoagulant Therapy
- Cytochrome P450
- Sickle-cell Disease
- Antithrombotic Therapy
- Advanced Glycation End Products
- Bone Health
- HMGB1
- Post-acute COVID-19 Syndrome
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 16 words, with their numbers
- Anticoagulant Therapy71 topic
- Atrial Fibrillation71 topic
- Cytochrome P45051 topic
- Pharmacogenetics51 topic
- Sickle-cell Disease51 topic
- Thalassemia51 topic
- Antithrombotic Therapy41 topic
- Venous Thromboembolism41 topic
- Advanced Glycation End Products31 topic
- Aspirin31 topic
- Bone Health31 topic
- Clopidogrel31 topic
- HMGB131 topic
- Neurologic Manifestations31 topic
- Post-acute COVID-19 Syndrome31 topic
- Vitamin K31 topic
Where does Salah Abohelaika work?
Salah Abohelaika's main affiliation in the publication record is Qatif Central Hospital, Saudi Arabia.
How many publications and citations does Salah Abohelaika have?
OpenAlex counts 33 works and 311 citations for Salah Abohelaika, an h-index of 9, ranking #2,641,490 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Salah Abohelaika. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.